Clinical Trials Browser

INDUSTRY × Saline Solution × Gastrointestinal × Clear all

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT07219459 2026-04-27

GDFATHERHCC01

Phase 2 Recruiting

104 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

Phase 3 Completed

120 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05394714 2025-09-23

A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06910514 2025-04-09

Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions

Phase 3 Completed

52 enrolled

Gastrointestinal

Colonic Neoplasms

NCT01956812 2021-08-16

PANCRIT®-1

Phase 3 Terminated

334 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Phase 2 Completed

558 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT00851045 2015-10-12

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Phase 2 Completed

17 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

KEYNOTE 975

GDFATHERHCC01

KEYNOTE-585

KEYNOTE-585

A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study

Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions

PANCRIT®-1

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer